Evaluating a program to prevent anxiety in children of anxious parents: a randomized controlled trial

TL;DR

A program for anxious parents aimed at preventing anxiety in their children showed mixed results, with some benefits for younger children but no overall significant effect after 12 months.

Contribution

The study evaluates a novel parent-focused intervention to prevent anxiety disorders in children of anxious parents through a randomized controlled trial.

Findings

No significant difference in clinical severity ratings between the intervention and control groups overall.

Children aged 5–6 years in the intervention group showed lower risk of increased anxiety severity and diagnosis.

CPBC children had larger decreases in anxiety symptoms compared to controls, but parental self-efficacy improved similarly in both groups.

Abstract

Pediatric anxiety disorders are prevalent, particularly among children with anxious parents. This trial evaluated a program for anxious parents aimed at preventing offspring anxiety disorders and symptoms over 12 months.

This parallel, randomized, controlled, open‐label trial was conducted at Karolinska Institutet, Stockholm, Sweden. Inclusion criteria comprised heightened parental anxiety and the child (5–9 years old) not currently meeting criteria for an anxiety disorder. The program, Confident Parents–Brave Children (CPBC) involves six video conferencing group sessions. An external researcher randomly allocated (1:1) participants to CPBC or a self‐help control. The primary outcome was change in clinical severity ratings (CSR) between pre‐ and 12‐month assessments, assessed by the Anxiety Disorders Interview Schedule. Secondary outcomes included parent‐rated child anxiety symptoms and parental self‐efficacy. The study was preregistered at ClinicalTrials.gov (NCT04722731).

The trial included 215 parents (91% female) and 277 children (48% girls, mean age 7.0). At the 12‐month assessment, no statistically significant difference was found between conditions on the primary outcome (change in CSR), OR = 0.67 (95% CI: 0.30, 1.48). No statistically significantly lower prevalence of anxiety disorder at the 12‐month assessment was found in the CPBC group compared with the control group, OR = 0.57 (95% CI: 0.24, 1.31). When stratifying by age, children 5–6 years in CPBC showed lower risk of increased CSR, OR = 0.24 (95% CI: 0.08, 0.77), and anxiety diagnosis, OR = 0.23 (95% CI: 0.05, 0.84), compared to controls. Regarding secondary outcomes, CPBC children exhibited larger decreases in anxiety symptoms than control children from pre‐ to the 12‐month assessment, Cohen's d = .35 (95% CI: 0.15, 0.55). Parents in both conditions showed increased parental self‐efficacy over time, with no significant between‐group effect. The 12‐month assessment was completed by 204 parents (95%).

The CPBC may have potential for preventing anxiety in young children; however, further research is warranted.

Figures